Nuzzi Raffaele, Tridico Federico
Eye Clinic Section and Specialization School in Ophthalmology, Institute of Ophthalmology, Department of Clinical Pathophysiology, University of Turin, Via Juvarra 19, 10100 Turin, Italy.
J Ophthalmol. 2017;2017:6824670. doi: 10.1155/2017/6824670. Epub 2017 May 28.
To evaluate the efficacy of subconjunctival bevacizumab injections, before and after surgical excision with bare sclera technique, in preventing postoperative pterygium recurrence.
83 eyes of 83 patients affected with primary pterygia underwent surgical excision. 42 eyes received two subconjunctival bevacizumab injections, at the dosage of 2.5 mg/0.1 ml, one week prior surgery and one week after intervention. Recurrence rate was evaluated among the two groups. Moreover, modifications of pterygium size and grade one week after the first injection were evaluated.
At 6 months after surgery, the recurrence rate was 7.14% in the bevacizumab group and 24.39% in the control group. Significant changes of pterygium size and grade were reported after the first injection. No important complications related to bevacizumab subconjunctival injections were registered.
The application of subconjunctival bevacizumab injections, at the dosage of 2.5 mg/0.1 ml, before and after surgical pterygium excision, may be useful in preventing lesion recurrence after bare scleral procedures. Furthermore, bevacizumab subconjunctival administration is well tolerated and may represent a safer alternative if compared with other surgical techniques and adjunctive drugs. This trial is retrospectively registered with ISRCTN Registry on 18 April 2017, TRN: ISRCTN11424742.
评估在采用单纯巩膜技术手术切除翼状胬肉前后结膜下注射贝伐单抗预防术后翼状胬肉复发的疗效。
83例原发性翼状胬肉患者的83只眼接受了手术切除。42只眼在手术前一周和干预后一周接受了两次结膜下贝伐单抗注射，剂量为2.5mg/0.1ml。评估两组的复发率。此外，还评估了首次注射后一周翼状胬肉大小和分级的变化。
术后6个月，贝伐单抗组的复发率为7.14%，对照组为24.39%。首次注射后翼状胬肉大小和分级有显著变化。未记录到与结膜下注射贝伐单抗相关的重要并发症。
在翼状胬肉手术切除前后应用剂量为2.5mg/0.1ml的结膜下贝伐单抗注射，可能有助于预防单纯巩膜手术后病变复发。此外，结膜下注射贝伐单抗耐受性良好，与其他手术技术和辅助药物相比可能是一种更安全的选择。本试验于2017年4月18日在ISRCTN注册中心进行回顾性注册，注册号：ISRCTN11424742。
